<code id='373D490FDE'></code><style id='373D490FDE'></style>
    • <acronym id='373D490FDE'></acronym>
      <center id='373D490FDE'><center id='373D490FDE'><tfoot id='373D490FDE'></tfoot></center><abbr id='373D490FDE'><dir id='373D490FDE'><tfoot id='373D490FDE'></tfoot><noframes id='373D490FDE'>

    • <optgroup id='373D490FDE'><strike id='373D490FDE'><sup id='373D490FDE'></sup></strike><code id='373D490FDE'></code></optgroup>
        1. <b id='373D490FDE'><label id='373D490FDE'><select id='373D490FDE'><dt id='373D490FDE'><span id='373D490FDE'></span></dt></select></label></b><u id='373D490FDE'></u>
          <i id='373D490FDE'><strike id='373D490FDE'><tt id='373D490FDE'><pre id='373D490FDE'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          comprehensive

          author:comprehensive    - browse:94793
          close-up of psoriasis on a hand. -- biotech coverage from STAT
          A close-up of psoriasis on a hand. Adobe

          San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

          Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

          advertisement

          Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge